Previous close | 0.1000 |
Open | 0.0900 |
Bid | 0.0950 x 0 |
Ask | 0.1000 x 0 |
Day's range | 0.0900 - 0.1100 |
52-week range | 0.0300 - 0.1100 |
Volume | |
Avg. volume | 173,827 |
Market cap | 24.886M |
Beta (5Y monthly) | 1.41 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0300 |
Earnings date | 29 Apr 2024 - 03 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
MISSISSAUGA, Ontario, February 28, 2024--MedX Health Corp. ("MedX" or the "Company") (TSXV: MDX), a global leader in teledermatology, is pleased to announce they have successfully completed the pilot project with Health Partners. MedX and Health Partners are working together to begin the roll-out of this service to targeted clients engaged in a preventative approach to health care management.
MISSISSAUGA, Ontario, January 25, 2024--MedX Health Corp. ("MedX" or the "Company") (TSX VENTURE: MDX) is pleased to announce that it has appointed Dr. Paul Cohen, a board-certified dermatologist and Fellow of the Royal College of Physicians and Surgeons of Canada, as Medical Spokesperson. Dr. Cohen is also a diplomat of the American Board of Dermatology and is a member of numerous associations, including the Canadian Dermatological Association and the Toronto Dermatological Society. He was awar
MISSISSAUGA, Ontario, December 12, 2023--MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX) is pleased to announce that it is making an Application to the TSX-V for Acceptance of the proposed amendment to the terms of the currently outstanding Convertible Loan Notes ("Series I Notes"). Following the conversion of five Series I Loan Notes during 2021, there are currently 75 Series I Loan Notes outstanding, with a face value of $3,750,000. The Series I Loan Notes, originally issued in the Fi